Acucela announced the publication of an article concerning the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Drug Discovery Today.
The published article, “Pharmacotherapy for Metabolic and Cellular Stress in Degenerative Retinal Diseases,” can be accessed here.
Authors of the paper explored the cellular and metabolic stressors associated with degenerative retinal diseases and the potential role of visual cycle modulation with emixustat in the treatment of these diseases. The accumulation of toxic visual cycle byproducts and retinal hypoxia are stressors associated with retinal diseases such Stargardt disease (STGD) and diabetic retinopathy (DR), respectively. Emixustat’s mechanisms of action and preclinical data supporting the role of emixustat in the treatment of these diseases is detailed.
“I am pleased that this article on the role of emixustat in treating retinal degenerations has been published in the journal Drug Discovery Today. This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy. Advancing our clinical programs is what we are focusing on and we will continue to actively seek for partnership opportunities,” Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela, said in a company news release.
Emixustat has been formulated for oral administration and is currently being investigated in a multicenter phase 3 clinical trial to determine if emixustat reduces the rate of macular atrophy progression, in comparison to placebo, in subjects with Stargardt disease. Secondary objectives include assessing changes in visual function parameters such as best-corrected visual acuity (BCVA) letter score and reading speed (Clinicaltrials.gov identifier: NCT03772665).